|
End-of-day quote
Berne S.E.
30/09/2026
|
5-day change | 1st Jan Change | ||
| 135.88 CHF | -2.33% |
|
-1.13% | -6.19% |
| 01/10 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 30/09 | Major drugmakers turn to China for licensing deals | RE |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 246,551 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -14.34% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 266,245 | 258,482 | 249,739 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -14.44% | -2.92% | -3.38% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20.3x | 17.7x | 15.3x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.57x | 3.99x | 3.45x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1x | 1.2x | 1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.9x | 3.68x | 3.47x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.21x | 3.86x | 3.51x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12x | 10.6x | 9.31x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.6x | 11.1x | 9.78x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 27.8x | 19.9x | 17.1x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.6% | 5.03% | 5.85% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.34 | 3.544 | 3.655 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.1% | 2.23% | 2.3% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.844 | 8.987 | 10.37 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.6% | 39.4% | 35.2% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,172 | 67,008 | 71,142 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,193 | 24,358 | 26,836 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,100 | 23,268 | 25,545 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,044 | 13,773 | 15,801 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,694 | 11,931 | 3,188 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 158.96 | 158.96 | 158.96 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 10/2/22 | 9/2/23 | 8/2/24 | 6/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.9x | 11.93x | 24.23x | 0.6% | 1,031B | |
| 29.45x | 6.54x | 18.31x | 2.02% | 638B | |
| 33.1x | 7.75x | 16.02x | 2.65% | 462B | |
| 105.72x | 5.91x | 25.05x | 2.35% | 359B | |
| 19x | 4.63x | 11.48x | 2.87% | 335B | |
| 20.37x | 5.28x | 13.08x | 3.03% | 273B | |
| 20.79x | 4.31x | 12.28x | 2.05% | 253B | |
| 26.62x | 6.92x | 12.32x | 2.39% | 228B | |
| -45.08x | 6.57x | 25.65x | 2.21% | 185B | |
| Average | 26.98x | 6.65x | 17.60x | 2.24% | 418.21B | |
| Weighted average by Cap. | 32.10x | 7.72x | 18.90x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- 000982352 Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
